Skip to content
Open access · OA via OpenAlex

Low-Dose Naltrexone as a Potential Healthspan-Enhancing Intervention in a Normative Aging Cohort: Changes in Quality of Life and Immune Health Metrics

Girish Harinath, Sajad Zalzala, Andy Nyquist, Maartje C.A. Wouters, Anar Isman, Brandon Verkennes

· 2024 · ▲ 1 citations

Abstract

Low-dose naltrexone (LDN) has been suggested to target the multiple telomere(definition) attrition, cellular senescence(definition))." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">hallmarks of aging(definition) and improve healthspan(definition) metrics in humans.However, to date, no studies have evaluated LDNs potential as a gerotherapeutic.We collected real-world data utilizing the short form 36 quality of life (QoL) assay, immune status questionnaire, and a patient-reported health assessment to evaluate the effectiveness of LDN for improving multiple healthspan metrics in a normative aging cohort still within their healthspan.Most participants taking LDN for ≥3 months (69.2%) had a significant improvement in mean QoL scores (29.9%).The largest improvements were observed in the QoL categories of energy and fatigue, physical role limitations, emotional role limitations, social functioning, and pain.Participants also exhibited a significant improvement in mean immune function (24.6%).Data from a patient-reported health assessment at ≥4 weeks (N = 5500) and ≥10 weeks (N = 1450) of LDN use revealed that a majority of participants reported improvements in pain, fatigue, inflammation, and mood.A healthspan-enhancing drug should demonstrate the ability to enhance the health of individuals before significant age-related diseases and disability arise, thereby extending the period of life spent in good health.We found that 45% of responders to LDN had average to above-average baseline QoL scores, which increased to 76.6% of responders after LDN treatment.Furthermore, 23.8% of individuals taking LDN were able to discontinue other medications and 10.5% of participants reported avoiding planned clinical procedures.These data suggest that LDN might play a role in enhancing healthspan, warranting further research into its potential geroprotective effects.AgingBio, 2, e20240032,

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.59368/agingbio.20240032
Canonical
link ↗
Fetched
2026-10-07 MST

Cite this

APA
Harinath, G., Zalzala, S., Nyquist, A., Wouters, M.C., Isman, A., & Verkennes, B. (2024). Low-Dose Naltrexone as a Potential Healthspan-Enhancing Intervention in a Normative Aging Cohort: Changes in Quality of Life and Immune Health Metrics. https://doi.org/10.59368/agingbio.20240032
Vancouver
Harinath G, Zalzala S, Nyquist A, Wouters MC, Isman A, Verkennes B. Low-Dose Naltrexone as a Potential Healthspan-Enhancing Intervention in a Normative Aging Cohort: Changes in Quality of Life and Immune Health Metrics. 2024. doi:10.59368/agingbio.20240032.
BibTeX
@article{girish2024LowDos, title = {Low-Dose Naltrexone as a Potential Healthspan-Enhancing Intervention in a Normative Aging Cohort: Changes in Quality of Life and Immune Health Metrics}, author = {Girish Harinath and Sajad Zalzala and Andy Nyquist and Maartje C.A. Wouters and Anar Isman and Brandon Verkennes}, year = {2024}, doi = {10.59368/agingbio.20240032}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings